Melanoma vaccine in phase 3: towards approval in 2025
Moderna and Merck's vaccine reduces melanoma death rate by 62%, moving closer to FDA approval in 2025
Moderna and Merck's vaccine reduces melanoma death rate by 62%, moving closer to FDA approval in 2025
Experts say mRNA technology has accelerated the development of remedies against cancer, cardiovascular and autoimmune diseases.
The drug company could "cash in on" the mRNA cancer vaccine it is helping to deliver.
In a video call with investors, Moderna warns of new waves coming for Covid-19
Alberto Robiati and Gianluca Riccio guide readers through scenarios of the future: the opportunities, risks and possibilities we have to create a possible tomorrow.
News about the world of tomorrow.
We give news about the future of technology, science and society: if there is one thing that is about to arrive, it has already arrived here.
Category
Language editions
© 2024 Near future - This work is distributed under license Creative Commons Attribution 4.0 International.